跳至主要内容
临床试验/NCT00139607
NCT00139607终止3 期

A Multicenter, Open Label, Pilot Study To Evaluate Analgesic Activity And Safety Of Parecoxib 40 Mg IV In Patients Undergoing Hemicolectomy, In The Optimal Management Of Acute Post-Operative Pain Of Surgical Patients

Pfizer4 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2002年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
Pfizer
入组人数
60
试验地点
4
主要终点
Evaluation of efficacy assessments based on pain intensity (VAS) and on Pain relief (PR).

研究概览

简要总结

This is a phase III, multicenter, open label, pilot to evaluate the analgesic efficacy and safety of parecoxib 40 mg IV in the treatment of the pain following hemicolectomy in an optimal management of the surgical patient

详细描述

The study was terminated prematurely due to recruitment issues on 31 January 2006. Safety concerns did not lead to the decision to terminate this study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients hospitalised for resection of left/right colon;
  • preoperative health graded as ASA <3.

排除标准

  • patients with any type of metastatic cancer, particularly metastatic colon cancer;
  • patients with familial adenomatous polyps (sporadic adenomatous polyps are accepted);

结局指标

主要结局

Evaluation of efficacy assessments based on pain intensity (VAS) and on Pain relief (PR).

次要结局

  • Time between the first administration of parecoxib and the first request of morphine The total amount of morphine in the first 24 hours of treatment and the total amount of morphine given during the entire period of treatment with parecoxib

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (4)

Loading locations...

相似试验